"Red chip of state owned enterprises" Shanghai Pharmaceutical (02607) acquires the antitumor drug of yew extract

Shanghai Pharmaceutical (02607) (Shanghai: 601607) announced that in order to integrate the anti-tumor drug industry chain of Shanghai Pharmaceutical and develop gap planting base of traditional Chinese medicine, Shanghai Huayu pharmaceutical, a wholly-owned subsidiary of Shanghai pharmaceutical, and Shanghai Jin and biotechnology, a holding subsidiary of Shanghai Jin and biotechnology, invested RMB 160.1 million and RMB 110 million respectively in cash, through the transfer of Yunnan dalikangya biotechnology The way of equity and capital increase of Dali Zhonggu Taxus biology ultimately obtained 40% equity and 27.5% equity of Zhonggu biology to realize the holding of Zhonggu biology Zhonggu biological's business scope includes: Taxus, planting, sales, and preparation of processing projects Its main business is planting and selling rare Taxus chinensis, which can extract the key intermediate of antitumor drugs, 10dabiii Zhonggu biological's core assets are nearly 5.52 million Taxus seedlings and trees in Dali Prefecture, Yunnan Province, and related forest land use rights (EC)